Search Our Site

Australian researchers develop 10-minute cancer test

Australian researchers develop 10-minute cancer test

Researchers in Australia have developed a 10-minute test that can detect the presence of cancer cells anywhere in the human body, according to a newly published study. The test was developed after researchers from the University of Queensland found that cancer forms a unique DNA structure when placed in water. The test works by identifying... Read More »

Read More →

Researchers in Australia have developed a 10-minute test that can detect the presence of cancer cells anywhere in the human body, according to a newly published study. The test was developed after researchers from the University of Queensland found that cancer forms a unique DNA structure when placed in water. The test works by identifying… Read More »

[...]

Read More

Government Investigation Finds Flaws In the FDA’s Orphan Drug Program

The Food and Drug Administration has failed to ensure that drugs given prized rare-disease status meet the intent of a 35-year-old law, federal officials revealed in a report Friday. The Government Accountability Office, which spent more than a year investigating the FDA’s orphan drug program, said “challenges continue” in the program that was created to... Read More »

Read More →

The Food and Drug Administration has failed to ensure that drugs given prized rare-disease status meet the intent of a 35-year-old law, federal officials revealed in a report Friday. The Government Accountability Office, which spent more than a year investigating the FDA’s orphan drug program, said “challenges continue” in the program that was created to… Read More »

[...]

Read More

Pfizer to raise prices on 41 drugs despite earlier deferral on price hikes

The company emphasized that the increases mostly amount to 3-5 percent and affect only 10 percent of its portfolio, but declined to reveal which drugs are affected. Despite putting on hold a plan to increase prices on a host of its drugs, Pfizer said it will nevertheless raise prices on more than three dozen in... Read More »

Read More →

The company emphasized that the increases mostly amount to 3-5 percent and affect only 10 percent of its portfolio, but declined to reveal which drugs are affected. Despite putting on hold a plan to increase prices on a host of its drugs, Pfizer said it will nevertheless raise prices on more than three dozen in… Read More »

[...]

Read More

Amid shocks and burns, spinal-cord stimulators are more dangerous than many patients know

In this Nov. 16, 2018, photo, Jim Taft watches The History Channel from the confines of his bed at his home in West Columbia, S.C. Mr. Taft has experienced debilitating health issues after a neurosurgeon implanted Boston Scientific’s Precision spinal cord stimulator in his back in 2014.  (AP photo/Sean Rayford)   COLUMBIA, South Carolina —... Read More »

Read More →

In this Nov. 16, 2018, photo, Jim Taft watches The History Channel from the confines of his bed at his home in West Columbia, S.C. Mr. Taft has experienced debilitating health issues after a neurosurgeon implanted Boston Scientific’s Precision spinal cord stimulator in his back in 2014.  (AP photo/Sean Rayford)   COLUMBIA, South Carolina —… Read More »

[...]

Read More

Expensive, name-brand medications drive up drug spending

Three costly rheumatoid arthritis drugs lead the pack in drug spending, the new analysis shows. A pharmacy employee dumps pills into a pill counting machine.Lucas Jackson / Reuters, file Pricey, name-brand prescription medications continue driving up drug spending even though more patients are getting cheaper generics, according to a study released Wednesday. And the spending... Read More »

Read More →

Three costly rheumatoid arthritis drugs lead the pack in drug spending, the new analysis shows. A pharmacy employee dumps pills into a pill counting machine.Lucas Jackson / Reuters, file Pricey, name-brand prescription medications continue driving up drug spending even though more patients are getting cheaper generics, according to a study released Wednesday. And the spending… Read More »

[...]

Read More

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

UniQure has posted eagerly-anticipated data on the modified hemophilia B gene therapy it plans to take into phase 3. The FIX-Padua variant therapy achieved factor IX (FIX) activity levels of 23% to 37%, suggesting it is several times more effective than the version uniQure tested in earlier-phase trials. Throughout development of its earlier, wild-type FIX... Read More »

Read More →

UniQure has posted eagerly-anticipated data on the modified hemophilia B gene therapy it plans to take into phase 3. The FIX-Padua variant therapy achieved factor IX (FIX) activity levels of 23% to 37%, suggesting it is several times more effective than the version uniQure tested in earlier-phase trials. Throughout development of its earlier, wild-type FIX… Read More »

[...]

Read More

AI tool predicts Alzheimer’s more than 6 years ahead of diagnosis

A deep learning algorithm developed using imaging data from more than 1,000 Alzheimer’s disease (AD) patients can accurately predict the presence of AD more than six years before a doctor finalizes a diagnosis, researchers reported in Radiology Nov. 6. While it’s globally acknowledged that a timely diagnosis is linked to prognosis in Alzheimer’s patients, physicians... Read More »

Read More →

A deep learning algorithm developed using imaging data from more than 1,000 Alzheimer’s disease (AD) patients can accurately predict the presence of AD more than six years before a doctor finalizes a diagnosis, researchers reported in Radiology Nov. 6. While it’s globally acknowledged that a timely diagnosis is linked to prognosis in Alzheimer’s patients, physicians… Read More »

[...]

Read More

E-Alerts Dramatically Cut Heart Attack Rate for People Hospitalized With A-Fib

A simple pop-up alert on a computer screen could help save the brains and hearts of many hospital-bound people with an irregular heartbeat, a new clinical trial reveals. Rates for heart attack and stroke plunged by close to 90 percent in people helped by the new program, the study found. The computer alert warns doctors... Read More »

Read More →

A simple pop-up alert on a computer screen could help save the brains and hearts of many hospital-bound people with an irregular heartbeat, a new clinical trial reveals. Rates for heart attack and stroke plunged by close to 90 percent in people helped by the new program, the study found. The computer alert warns doctors… Read More »

[...]

Read More

Treatment for Diffuse Large B-cell Lymphoma Gets FDA Fast Track Designation

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy, according to Karyopharm Therapeutics, Inc., the manufacturer of the first-in-class SINE compound.1 The designation... Read More »

Read More →

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy, according to Karyopharm Therapeutics, Inc., the manufacturer of the first-in-class SINE compound.1 The designation… Read More »

[...]

Read More

Blue Cross changes opioid coverage, drops standard OxyContin

Blue Cross and Blue Shield of Alabama has announced new changes to its opioid policy, including a decision that the insurer will no longer cover the standard formulation of OxyContin. The news, released Tuesday, is at least the second time this year that the insurer has changed its handling of opioids. In March it set... Read More »

Read More →

Blue Cross and Blue Shield of Alabama has announced new changes to its opioid policy, including a decision that the insurer will no longer cover the standard formulation of OxyContin. The news, released Tuesday, is at least the second time this year that the insurer has changed its handling of opioids. In March it set… Read More »

[...]

Read More

Page 3 of 51

Categories
Archives